key: cord-1023481-l98ct0nt
authors: Mendez, Lucas C.; Raziee, Hamid; Davidson, Melanie; Velker, Vikram; D'Souza, David; Barnes, Elizabeth; Leung, Eric
title: Should we embrace hypofractionated radiotherapy for cervical cancer? A technical note on management during the COVID-19 pandemic
date: 2020-05-28
journal: Radiother Oncol
DOI: 10.1016/j.radonc.2020.05.032
sha: 089c1c1612e05bef3790c93a83afd1da1070f181
doc_id: 1023481
cord_uid: l98ct0nt

Cervical cancer is a deadly disease and the COVID-19 pandemic has the potential to further impact its lethality. Hypofractionated radiotherapy could mitigate this impact, however robust data in cervical cancer setting still is lacking. Information provided here could help institutions in reducing radiotherapy fractions for cervical cancer patients.

Dear Editor(s), Cervical cancer continues to be a frequent source of morbidity and mortality among women worldwide with more than 310,000 deaths per year (1) . Approximately 85% of theses fatalities occur in low-and middle-income countries (LMIC) (2) , where multiple factors including insufficient screening programs, referral delays and an unmet gap between treatment need and availability play a role in this serious global health issue.

The current COVID-19 pandemic has the significant potential to further impact cancer treatment delivery globally including within high income countries.

Strategies to reduce viral spread such as physical distancing or reducing the frequency of interaction between patient and staff have been advocated in an effort to flatten the transmission curve, potentially affecting the routine delivery of oncological treatments. In addition, funding reallocation to the front line of pandemic control could have a negative impact on resources available to oncological services, especially in LMICs already working under strained healthcare systems (3, 4) .

Radiotherapy plays an integral role in the curative treatment of locallyadvanced cervical cancer, and in light of the foreseeable reduction in surgical procedures amid the current pandemic crisis, may be increasingly used as first-line treatment in early-stage cervical malignancies. Radiation therapy has also experienced a transformational evolution in recent decades driven by technological advances including 3D planning, intensity-modulated radiotherapy and image-guidance. These advances have allowed for a higher degree of treatment precision and facilitated a reduction in the number of radiotherapy fractions in a variety of disease sites. As a result, hypofractionation has not only the capacity to increase convenience and efficiency, but also to mitigate radiotherapy shortages faced especially by cancer treatment services in LMIC. Likewise, hypofractionation may be even more relevant in these current times due to worldwide shortages of resources, including in radiotherapy, related to the COVID-19 pandemic (5) .

There is still a need for further large-scale studies on hypofractionated radiotherapy for cervical cancer, however, prospective data has shown some promise in shorter schedules of radiation. In a phase I-II trial from Brazil, 34 patients with stage IIIB cervical cancer were treated with hypofractionated radiotherapy together with concurrent 5-fluorouracil 400 mg/m2 and cisplatin 15mg/m2 given on days 1-3, 15-17, 45-47, and 59-61. The whole pelvis was treated with a four-field box technique to a total dose of 40Gy with BID fractions of 2.5Gy on days 1, 3, 15, 17, 45, 47, 59 and 61. Low-dose rate brachytherapy with 35Gy prescribed to point A was delivered on day 29. All patients concluded treatment and this was considered well tolerated, with no grade 3 or 4 acute toxicity. Four and 1 patients developed late grade 3 or 4 gastrointestinal and urinary toxicity, respectively. Complete response rate was 85% and the 5-year overall survival rate was 59% (6).

In another report coming from South Africa, 104 patients with stage IIIB cervical cancers were treated with external beam radiotherapy (EBRT) 40 Gy in 16 daily fractions (AP/PA fields) plus brachytherapy with 9 Gy x 2 fractions. No concurrent chemotherapy was given and outcomes were reported retrospectively.

Complete response was registered in 70% of patients and disease free-survival (DFS) at 20 months was 59%. No late GU toxicities were seen, while 4 late GI toxicity were registered (7) . A retrospective report from Tata Memorial investigated the role of hypofractionated radiotherapy in 62 stage IIIB cervical cancer patients treated with 39 Gy in 13 daily fractions (mostly AP/PA fields) followed by intracavitary brachytherapy. The 5-year DFS rate was 59%, and 5 patients had late G3 rectal toxicity (8) .

Altogether, the experience of these three clinical series, with a total of 200 stage IIIB cervical cancer patients treated with hypofractionated radiotherapy with or without chemotherapy, provides some insight into this treatment strategy. Although heterogeneity among series is perceptible, with differences mostly in treatment delivery and chemotherapy use, some conclusions can be formulated. First, hypofractionated radiotherapy with a total dose of 39-40 Gy and fractions ≥ 2.5Gy (followed by brachytherapy boost) may lead to a reasonable tumour response considering the patient population included and the brachytherapy technique offered.

Second, concurrent chemotherapy with hypofractionated radiotherapy is possible and did not lead to exacerbated levels of late toxicity in the Brazilian experience, despite use of conformal technique only. Lastly, G3-4 late toxicities were seen in approximately 10-15% of patients. This is roughly similar to most modern series (9), withstanding differences in data collection.

Currently, an ongoing Mexican phase II trial is randomizing patients with locally advanced cervical cancer between EBRT with 45 Gy/ 25 fractions or 37.5

Gy/15 fractions. EBRT is being delivered with a 4-field box and weekly concurrent cisplatin followed by brachytherapy boost to point A with 28 Gy in 4 fractions in both arms (10) . In Canada, funding has been secured for a multi-centric Phase 2 randomized trial (Hypofractionated External-beam RadiOtherapy for Intact Cervical Cancer (HEROICC)-Trial) that randomizes cervical cancer patients between two experimental hypofractionated radiotherapy regimens. Different from studies reported above, this trial seeks to only include patients with a small bulk of primary disease and a low burden of nodal spread ( Table 1 ). The rationale behind this inclusion criteria is to ensure optimal high-risk CTV (CTV HR ) coverage at the time of brachytherapy, assuming that the downsizing of larger primary tumours might not be optimal at EBRT completion with hypofractionation if compared to longer standard regimens. If this assumption is true, offering hypofractionated radiotherapy to large primary tumours could increase the need for more sophisticated brachytherapy, such as comprehensive interstitial techniques, due to unfavourable geometry at the time of brachytherapy implant. Of note, radiation will be given using intensity-modulated technique and with concurrent weekly cisplatin.

While it would be ideal to have more robust data before changing fractionation protocols in this curative disease, limitation and depletion of resources due to COVID-19 pandemic may require the consideration of shortening treatment schedules. The practical resource and disease implications of staying with standard fractionation may result in reduced overall access to radiotherapy. It could also potentially lead to suboptimal outcomes, if treatment fractions are interrupted, in patients who become suspected or infected with COVID-19. Conscientious of the international effort to mitigate havoc caused by the COVID-19 pandemic and acknowledging a decreased allocation of resources for oncological patients, investigators from the HEROICC-trial have report on planning constraints and rationale related to Arm 1 of this study protocol (Tables 1-2) .

The authors would like to state that there is no indication that the suggested dose-fractionation is effective for tumour control or safe to the surrounding organs at risk. The intended aims of the HEROICC trial are in fact to investigate these questions. However, the following points provide our rationale for the dosimetric choices made for the HEROICC-trial, for institutions considering a hypofractionated option. As the role of overall treatment time is known to be predictive of cancer control in cervical cancers, it is fair to hypothesize that larger true BEDs can be achieved with faster treatment deliveries. 

This technique has been shown to reduce dose to bowel and bladder and to reduce acute adverse effects like diarrhea. IMRT also improves patient-reported outcomes (PRO), as bowel and urinary domains were less impacted when compared to four-field box radiotherapy (13) .

Differences in toxicity and PRO between treatment modalities persisted at 1-and 3-years post treatment (14) . Table 2 rely in an institutional planning study developed for this trial purpose. In this, fifteen cervical cancer patients were planned with this suggested approach and 60% of these patients have met all optimal constraints in Table 2 . Five patients failed to meet the optimal bowel constraint (V3450cGy<100cc) but met the alternative constraint (V3450cGy<250cc). This alternative value, however, will be difficult to be met in patients with an excess of 250cc of bowel in the PTV, as was the case with one of our fifteen patients. 80% and 90% of cases met the optimal rectum and bladder values, respectively, with all meeting the alternative constraints provided. While the optimum constraints for bladder and rectum may be difficult to achieve when more than 50% of the organ is encompassed by the PTV, the alternative values should provide reasonable flexibility in these instances (Internal Data-not published). To evaluate the negative dosimetric impact of the additional dose from SIB in planning, five of the most difficult cases were re-planned with two nodes being boosted to the proposed SIB dose. Bowel constraints became increasingly challenging to achieve with the inclusion of SIB volumes. Thus, we have increased the allowance of bowel dose in the SIB setting based on constraints derived from the NRG-GY006 clinical trial (15) .

In summary, the information presented here could serve as a practical method for institutions that require to decrease radiation utilization during the COVID-19 pandemic, while attempting to preserve radiation quality using a hypofractionated regimen. Of note, the protocol here presented is a prospective clinical trial and is not A EMBRACE (BED-scaled, alpha/beta=3Gy) B EMBRACE (linearly-scaled by: 40Gy/45Gy) C NRG-GY006 (BED-scaled, alpha/beta=3Gy) D NRG-GY006 (linearly-scaled by: 40Gy/45Gy) E BED-scaled from 50Gy<20cc (alpha/beta=3Gy)from Stanic et al 2013 (16), F BED-equivalent to 58Gy/25, alpha/beta=3Gy

Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries

Challenges in Prevention and Care Delivery for Women with Cervical Cancer in Sub-Saharan Africa. Front Oncol

A Systematic Review of Radiotherapy Capacity in Low-and Middle-Income Countries. Front Oncol

Cancer Deaths due to Lack of Universal Access to Radiotherapy in the Brazilian Public Health System

COVID-19: Global radiation oncology's targeted response for pandemic preparedness

Concurrent chemotherapy and hypofractionated twice-daily radiotherapy in cervical cancer patients with stage IIIB disease and bilateral parametrial involvement: A phase I-II study

A retrospective study of advanced carcinoma of the cervix treated with a hypofractionated radiation therapy protocol at the department of radiation oncology

Hypofractionated radiotherapy in carcinoma cervix IIIB: Tata Memorial Hospital experience

Image guided brachytherapy in locally advanced cervical cancer: Improved pelvic control and survival in RetroEMBRACE, a multicenter cohort study

Chemotherapy and Pelvic Hypofractionated Radiation Followed by Brachytherapy for Cervical Cancer

The EMBRACE II study: The outcome and prospect of two decades of evolution within the GEC-ESTRO GYN working group and the EMBRACE studies

Hypo-Fractionation in Muscle-Invasive Bladder Cancer: An Individual Patient Data (IPD) Meta-Analysis of the BC2001 and BCON Trials

Patient-Reported Toxicity During Pelvic Intensity-Modulated Radiation Therapy: NRG Oncology-RTOG 1203

IMRT Improves Late Toxicity Compared to Conventional RT: An Update on NRG Oncology-RTOG 1203

Testing the Addition of a New Anti-Cancer Drug, Triapine, to the Usual Chemotherapy Treatment (Cisplatin) During Radiation Therapy for Advanced-stage Cervical and Vaginal Cancers

Tolerance of the Small Bowel to Therapeutic Irradiation: A Focus on Late Toxicity in Patients Receiving Para-Aortic Nodal Irradiation for Gynecologic Malignancies